Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

@article{Gadelha2014PasireotideVC,
  title={Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.},
  author={M. Gadelha and M. Bronstein and T. Brue and M. Coculescu and M. Fleseriu and M. Guitelman and V. Pronin and G. Raverot and I. Shimon and Kayo Kodama Lievre and J. Fleck and M. Aout and A. Pedroncelli and A. Colao},
  journal={The lancet. Diabetes \& endocrinology},
  year={2014},
  volume={2 11},
  pages={
          875-84
        }
}
BACKGROUND Many patients with acromegaly do not achieve biochemical control despite receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide. [...] Key MethodMETHODS In a multicentre, randomised, phase 3 trial, we enrolled eligible patients aged 18 years or older with acromegaly who were inadequately controlled (5-point, 2 h mean growth hormone concentration >2·5 μg/L and insulin-like growth factor 1 [IGF-1] concentration >1·3 times the upper normal limit) and had received 30…Expand

Paper Mentions

Interventional Clinical Trial
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.  
ConditionsAcromegaly
InterventionDrug
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
...
1
2
3
...